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Summary 
Tuberculosis (TB) continues to kill more than 1.5 Mio people every year and causes a significant 
morbidity burden in the about 9 Mio patients who survived this infectious disease. Rapid and accurate 
TB diagnosis is considered one cornerstone of the global fight against TB. The “End TB Strategy” of the 
World Health Organization (WHO) is enforcing the need to develop new TB diagnostic tests, which are 
addressing the shortcomings of standard diagnostic tests that are currently used in TB epidemic and 
resource constrained settings like sub-Saharan Africa. In addition, to improved diagnostic tests, 
innovate testing strategies are needed to detect TB and control TB transmissions within specific risk 
groups such as prisoners, children and also TB contacts. 
In the frame of the presented habilitation project, three new diagnostic tests, namely the new Xpert 
MTB/RIF assay, which was endorsed by WHO in 2010, and two urine- based LAM tests, were evaluated 
in various clinical diagnostic studies in Tanzania. Further, a cross-sectional TB prevalence study was 
conducted in 13 Ethiopian prisons to study risk factors for TB in inmates and how successful currently 
implemented diagnostics algorithms are to detect TB in detention facilities. Finally, the isolated TB 
strains from these research studies were further analyzed using genotyping techniques in order to 
analyse mechanisms of TB transmission, spread of drug resistance and pathogenicity of TB strains in 
different high TB risk populations in Africa. 
For the Xpert MTB/RIF evaluation, the studies included adult and pediatric cohorts of patients with 
suspicion of TB. Further, the Xpert MTB/RIF assay was evaluated in a study with household contacts of 
smear-positive TB patients. Finally, the assay´s capacity to monitor TB treatment was assessed in TB 
patients who were enrolled in a therapeutic drug trial. The results of these studies contributed relevant 
information on the diagnostic accuracy of the assay and are also reflected by the current Xpert 
MTB/RIF policy recommendations from WHO. The most relevant findings were that Xpert MTB/RIF had 
a significant higher sensitivity compared to smear microscopy and detected up to 60% of smear 
negative, culture positive adult and paediatric TB cases. Xpert MTB/RIF performs equally well in HIV-
positive and HIV-negative TB suspects and only one test in adults is sufficient to reach almost maximal 
sensitivity. Due to easy handling, rapid availability of test results and good performance in field 
conditions, the Xpert MTB/RIF test should be considered as the preferred test in contact tracing 
scenarios in Tanzania. However, due to sustained positive Xpert MTB/RIF results until the end of 
antimicrobial therapy in up to 27% of smear-positive TB patients, this assay is not useful to monitor 
microbiological response to TB treatment. 
The diagnostic capacity of the two LAM-assays was evaluated in a cohort of children with presumed 
TB. This study showed that LAM-sensitivity was highest, with maximal 70%, in HIV positive TB cases 
but had poor sensitivity, 28%, in HIV-negative TB suspects. Importantly, those groups of children 
suffering most from (co-) morbidities and high mortality were more likely to be LAM-positive.  
Therefore, specifically HIV-positive children with presumed active TB infection and advanced morbidity 
might benefit most from urine LAM-testing. This is in line with current WHO recommendations on the 
use of urine-based LAM tests. However, further scientific evidence is needed for a final evaluation of 
the use of LAM tests for the diagnosis of TB in clinical routine in Africa. 
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The prison studies revealed that TB prevalence with about 450 TB cases among 100.000 convicts was 
twice as large as in the standard Ethiopian population. About 30% of existing TB cases were not 
detected by the prison health staff, whereby half on these were smear negative. Risk factors for TB in 
prisons were related to subject characteristics and behavior (e.g. alcohol drinking and TB contact at 
home) as well as to prison capacities (e.g. windows in prison cells). Genotypic analyses revealed that 
TB strains from prisoners were forming joint clusters with TB strains isolated from the Ethiopian 
standard population. These findings support the concept of interrelated TB epidemics among 
populations inside and outside prisons. Both sides need to be addressed in TB control programmes, 
and e.g. systematic and comprehensive TB screenings among new prisoners at entry as well as long-
term prisoners might be an important strategy in order to end TB in high risk populations in Africa.  
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1. Introduction 
1.1. Global burden of TB disease 
TB is one of the most common infectious disease worldwide (1). Estimated one-third of the global 
population is latently infected with TB mycobacteria. In 2015, about 10.4 Mio people developed active 
TB disease, out of whom about one Mio were children below the age of 19 years. Up to 11% of the 
newly diagnosed TB cases were co-infected with HIV. An estimate of 1.8 Mio people died as a 
consequence of TB activation and TB disease, among them 0.2 Mio children (1). Consequently, TB 
belongs to the top ten killers worldwide. In 2015 more human beings died from TB than HIV or malaria. 
The 2015 TB mortality rate in low and middle income countries was between 5% in few countries of 
Northern Africa and Asia and more than 20% in countries of sub-Saharan Africa (2). This difference in 
percentages is also reflecting the diversity in the availability and quality of TB diagnosis and treatment 
in the different countries (3). Further, there are differences in the vulnerability of the various 
populations for TB infection and death from TB which are mainly associated with the distribution of 
socio-economic determinates (3). 
In addition to the considerable mortality risk, active TB disease is associated with a high disease burden 
(4), which can last until far beyond the period of active infection (5, 6). Even years after the finalization 
of anti-mycobacterial therapy, a large proportion of TB patients suffers from the long-term 
consequences of TB disease, leading to a sustained reduction in the quality of life and shortened life 
expectancy (7-10). Mostly, chronic pulmonary impairment and consecutive heart disease are the 
medical reasons for this (11), but diabetes mellitus and cancer are also more frequently diagnosed in 
former TB patients (12, 13). In addition to the long term TB sequelae, active TB often represents a high 
risk of impoverishment for the entire family of the affected persons (14, 15), as well as social stigma 
and ostracism (16), especially in those countries most affected by TB. This underlines the importance 
of TB prevention measures in the population, including the availability of reliable diagnostic tests. An 
early diagnosis of TB prevents the transmission of the disease to other persons and allows the 
limitation of potential health (17, 18) and financial (19) damage to TB patients. 
1.2. The importance of diagnostic tests for TB control in Africa 
The achievement of successful TB control in the developed countries of the Western world up to the 
middle of the 20th century (20, 21) resulted in a diminishing interest of science in the development of 
new diagnostic tests and therapies. In addition to the introduction of antibiotic 4-fold therapy in the 
1950s and 1960s, progress in the public health sector and raising social and economic standards have 
made TB a rare disease in many Western countries Regions (21).  
It was only in 1991 that TB was again declared a serious global health problem by the World Health 
Assembly (22), and the DOTS strategy was developed in the 1990s with the aim to control TB on a 
global level. An important pillar of the DOTS strategy (of a total of five) was to ensure TB diagnosis by 
means of assured microbiological detection methods: "case detection through quality-assisted 
bacteriology" (23). The major aim of the WHO and the national TB programs was to stop TB 
transmission in the population. This was to be achieved mainly by a rapid diagnosis and effective 
antibiotic therapy. A decade after DOTS the WHO's Stop TB strategy was introduced, addressing 
additional challenges (such as the HIV co-epidemic in most sub-Saharan Africa), and setting out 
strategies for solutions. Again, an early and correct diagnosis of active TB as well as the promotion of 
research in this area were of particular importance: "Pursue high-quality DOTS expansion and 
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enhancement (Component 1)" & "Enable and promote research (component 6)" (24). Through the 
implementation of DOTS and the Stop TB strategy, some sub-Saharan African countries, including 
Tanzania and Ethiopia, have succeeded in achieving individual aims of the United Nations Millennium 
Development Goals (MDGs) and the Stop TB strategy (1). However, both countries, Tanzania and 
Ethiopia, still belong to the 20 "high TB burden" countries in 2015. Among other reasons, this 
classification as high burden country was mainly based on the ongoing high TB incidence in both 
countries. Although TB incidence and mortality rates in Tanzania and Ethiopia have declined 
significantly compared to 1990, there are still around 300/100.000 new cases per year in Tanzania and 
200/100.000 in Ethiopia. In addition to economic and social development aspects (3), the limited, 
comprehensive availability of TB diagnostics as well as the difficult diagnosis or accessibility of risk 
groups (HIV-positive, children, prisoners) are decisive factors for the lack of TB control in these 
countries. For example, the proportion of treated TB patients with bacteriologically confirmed TB in 
2015 was still only 54% in Ethiopia and 53% in Tanzania (1). 
The WHO and the United Nations have formulated the goal of ending the global TB epidemic by 2030. 
The WHO's "End TB Strategy", developed for this purpose, describes the most important measures and 
changes needed to achieve this ambitious goal worldwide. As part of the first component (A), the first 
pillar of this strategy emphasizes once again the importance of early and correct TB diagnosis, 
especially in specific risk groups: "Early diagnosis of TB, including universal drug-susceptibility testing, 
risk groups" (1). 
1.3. Standard diagnostic tests for detection of TB in Africa 
The gold standard of TB diagnosis represents the microbiological detection of mycobacteria in culture, 
either on solid or in liquid media, with a sensitivity of 80-85% and a specificity of about 98% (25, 26). 
In addition, the cultivation of mycobacteria is a prerequisite for the phenotypic determination of 
mycobacteria and the conduction of phenotypic resistance tests (27). The detection of active TB by 
means of cultural procedures is, however, also associated with disadvantages and specific 
requirements which can create additional financial and infrastructural hurdles, especially for 
developing countries in sub-Saharan Africa. On the one hand, the test requires that an adequate and 
sufficiently alive mycobacteria-containing clinical sample, usually sputum, can be obtained from the 
patients. This is often not possible, particularly in children and HIV patients, who either show too low 
bacterial load in the sputum or develop extra-pulmonary TB. Further, culturing methods last for an 
average of 1-3 weeks in liquid media and 3-8 weeks on solid media (26). Thus, they are very limited 
tools for the therapeutic monitoring of TB patients, since in the case of a negative culture growth up 
to eight weeks must be waited to obtain the final result. In addition, the predictive power of culture 
results for the occurrence of therapy failure or relapse is only unsatisfactory with 40% (28). 
Furthermore, the contamination with environmental organisms, e.g. NTM, particularly in Africa, is an 
additional differential-diagnostic challenge in the cultural detection of mycobacteria (29, 30). Finally, 
in particular, automated culture methods are expensive (cost more than ten euros per test) and also 
dependent on a functioning infrastructure (cold chain, electricity) and, not to forget, above-average 
trained staff. 
The by far most widely and most frequently used method for the detection of mycobacteria in sub-
Saharan Africa is the microscopy of sputum samples after staining, e.g. Ziehl-Neelsen staining or 
auramine staining (27). The advantages of this method are: (theoretical) independence from 
electricity, low costs and high specificity in symptomatic patients. Important disadvantages are, in 
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particular, the dependence on the investigator, the relatively high turnaround time required per 
sample, and the lack of sensitivity in specific subgroups (detection limit of 105 mycobacteria/ml of 
sputum) (31). The sensitivity of smear microscopy lays between 50-80% in adults with pulmonary TB 
(27). In children and HIV positive TB patients, it is significantly lower with 10% and 50%, respectively 
(32). Until recently, sputum microscopy was also used during follow-up of sputum-positive TB patients, 
to monitor anti-mycotic therapy in Africa. Because of the low predictive value of 24% for treatment 
failure (28), a positive sputum result at week eight of antibiotic therapy is currently no longer 
recommended as a basis for the extension of antibiotic therapy (intensive phase) by the WHO (33). 
The molecular detection of TB, in particular by PCR, played only a subordinate role for the diagnosis in 
African countries by the end of 2010, as the lack of infrastructure in most TB laboratories did not allow 
the development and implementation of an in-house PCR method. The commercialized line probe 
assays from Hain Lifescience GmbH (Hain test), which were based on the detection of mycobacterial 
DNA by hybridization of molecular probes after amplification of mycobacterial DNA by PCR, were used 
in only a few African laboratories, especially for species determination as well as rapid resistance 
testing in positive cultures (27, 34). The sensitivity and specificity of the different line probe assays as 
well as other PCR-based methods can reach up to 100%, if at least 105 organisms are present in the 
diagnostic sample (27, 34). Accordingly, sensitivity was significantly reduced (77% to 88%) when the 
MTBDRplus test from Hain was applied directly to sputum samples from adults with pulmonary TB (35, 
36). A sterile PCR lab is a requirement for the execution of the Hain tests, as well as appropriately 
trained staff. In addition, the tests´ costs are about 15-25 euros, depending on the test version, which 
is comparatively cost-intensive. 
With the endorsement of the Xpert MTB/RIF test, developed by the Cepheid Inc and the Foundation 
for Innovative New Diagnostics (FIND), by the WHO in December 2010, the situation changed suddenly. 
It seemed, this new assay had the potential to change the accuracy and strategy of TB diagnosis on the 
African continent fundamentally and sustainably. The Xpert MTB/RIF test, which is run on the 
GeneXpert testing machine, is a completely automated PCR method (37), which can also be carried 
out reliably by clinical personnel (38). The test duration for one sample is two hours and includes, in 
addition to the detection of mycobacteria of the tuberculosis complex, the detection of resistance 
against rifampicin. The sensitivity in a first worldwide study reached 90% with a specificity of up to 99% 
(39). However, this was the only available data when the test was endorsed in 2010. One test costs 
about 10 US dollars in Africa. With a detection limit of approximately 130 DNA copies per ml of sputum, 
the Xpert MTB / RIF test should be significantly more sensitive than sputum microscopy. The clinical 
evaluation of the Xpert MTB/RIF test in various patient populations was a major scientific focus of this 
habilitation project. 
A further diagnostic possibility that is specifically relevant in the countries of sub-Saharan Africa is the 
detection of mycobacterial antigen, especially lipoarabinomannan (LAM). LAM is a component of the 
cell wall of mycobacteria and is accordingly present in the sputum, blood and urine of tuberculosis 
patients (40). While the detection of LAM for diagnostic purposes in the sputum has not yet been 
successful (41), the TB diagnosis by LAM detection in the urine, especially in HIV-positive TB patients 
and possibly also in children, is considered an attractive alternative (40). In different studies, the 
reported sensitivity of LAM-detection in urine of adults was between 13% (42) and 67% (43), with best 
performance shown in HIV-positive TB patients with advanced immune-suppression (44). At the time 
point of the conduction of LAM-studies within this habilitation, no LAM- data were published yet for 
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children. If the first test generations were still relatively elaborate ELISA tests, Alere's urine-based LAM 
test is now available as a point-of-care rapid test. The evaluation of various LAM tests was also a 
scientific goal of this habilitation project. 
Immunological test methods are mentioned here only for the sake of completeness, since they were 
(almost) not used as TB diagnostics in the various studies within this habilitation work. So-called IGRA 
test methods, which are based on the detection of interferon-gamma-secreting T-lymphocytes in the 
peripheral blood of TB patients, play, mainly due to their complexity in the execution and 
interpretation of test results as well as due to costs, outside the research no role in Africa. On the other 
hand, positive skin tests, so-called Mendel Mantoux skin tests, are used in children with TB suspicion 
in order to estimate the probability of presence of active TB. Like the IGRA tests from blood, the skin 
tests are also based on the detection of immunological cells, especially T-memory cells, which after 
stimulation with a TB-specific antigen migrate into the skin and trigger a localized delayed-type 
immune reaction (45). 
1.4. Strategies for TB detection in specific populations in Africa  
Since some studies within the framework of this habilitation project deal specifically with the detection 
of TB, or the evaluation of new test strategies, in children and prisoners, the following are brief 
descriptions of the specificities and challenges of TB diagnosis in these two risk groups. 
In principle, the diagnosis of TB disease in children is comparably difficult, since children often present 
with atypical symptoms due to extra-pulmonary manifestations of the disease. In Africa, the diagnosis 
is further hampered by the presence of comorbidities such as malnutrition or HIV. In African countries, 
diagnostic scoring systems are frequently used in clinical practice (46-49), which, in addition to the 
clinical examination, also include the clinical history, the Mendel Mantoux skin test and radiological 
imaging. Unfortunately, almost all of these scores showed unsatisfactory diagnostic accuracy in various 
clinical trials (49, 50). The bacteriological detection of infection with mycobacteria, however, can only 
be achieved in a minority, often not more than 10%, of symptomatic children (27, 32). On the one 
hand, this is explained by the typically low bacterial load in children. On the other hand, sample 
collection is naturally associated with challenges in children and often not possible. Two different, 
semi-invasive procedures are available in Africa for sample collection in children with TB suspicion. The 
first one is the so-called sputum induction, where tracheal secretion is obtained by atomization of 
hypertonic saline solution via respiratory mask and subsequent nasal catheterization. Alternatively, 
the removal of sober-gastric juice by means of oesophageal catheterization is performed through the 
nose. Both methods show similar (low) success rates for the recovery of mycobacteria (51, 52). New 
diagnostic methods, based either on the use of alternative sample material, e.g. the urine for LAM 
testing, or with significantly higher sensitive than microscopy in sputum or gastric juice samples, e.g. 
the Xpert MTB/RIF test, are therefore extremely attractive candidates for clinical evaluation in 
children. 
TB is an important health problem in prisons worldwide, and especially in Africa. Various studies have 
shown that TB prevalence is constantly higher in prisons than in the normal population (53-55). This 
has various causes in Africa. On the one hand, TB risk factors such as low quality or even shortage of 
food, "overcrowding", lack of ventilation and lighting and limited medical care are closely linked to the 
usual conditions of detention facilities in Africa (54, 56). On the other hand, (potential) prisoners per 
se are constituting a TB risk populations because of their often low socioeconomic status (57) and pre-
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existing diseases such as HIV (58). Usually TB is diagnosed late in prisoners, e.g. if significant disease 
symptoms are present or the detection by sputum microscopy succeeds. More expensive and sensitive 
diagnostic methods, such as PCR or culture procedures, are often not available for prisoners in Africa. 
In a study conducted with Tanzanian prisoners, it was shown that 41% of the detainees who were 
presented in a hospital due to a relevant illness were actually affected by active TB (59). In addition to 
the understanding of specific risk factors and typical symptoms of active TB disease in prisoners, the 
development of cost-effective but effective screening tests or algorithms is necessary to quickly 
diagnose and treat TB in African prisons and by that prevent further spread of the bacilli to other prison 
inmates and to community members. 
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2. Scientific objectives 
The first, and main, focus of this habilitation was the clinical evaluation of different new diagnostic 
tests (Xpert MTB/RIF tests plus two different urine LAM-tests), as well as testing strategies for the 
detection of TB in different study populations in Tanzania. The main objective was to investigate the 
extent to which the new diagnostics are capable of supplementing or replacing the standard 
procedures (microscopy and culture).  
A second focus of this work was the investigation of various aspects related to TB prevalence among 
prisoners in Ethiopian detention facilities and the associated risk factors and transmission routes, 
which could guide future TB detection and TB control strategies in African prisons.  
In a third approach, the isolated TB strains from Tanzanian and Ethiopian studies were analyzed using 
genotyping methods with the aim to further characterize MTB strains circulating in East Africa, to 
explain possible TB transmission routes in the study populations and to assess the virulence of various 
MTB strains in HIV-positive TB patients. 
2.1. Evaluation of the molecular Xpert MTB/RIF assay in different Tanzanian study populations  
For the clinical evaluation of the new, and automated, molecular Xpert MTB/RIF assay, the following 
research objectives were in the main focus: 
- Description of diagnostic accuracy of Xpert MTB/RIF assay compared to culture as a reference 
standard in adults with suspected pulmonary TB and with and without HIV co-infection (60). 
- Description of diagnostic accuracy of Xpert MTB/RIF assay compared to culture and/or a 
clinical classification as reference standard in children with suspected pulmonary TB and with 
and without HIV co-infection (61). 
- Evaluation of Xpert MTB/RIF assay as TB screening method for household contacts of patients 
with smear positive pulmonary TB (62). 
- Evaluation of the Xpert MTB/RIF test compared to smear microscopy and culture methods as 
a marker for therapy monitoring in smear positive TB patients (63). 
2.2. Evaluation of various urine-based LAM assays for their diagnostic capacity in Tanzanian children 
For the evaluation of different urine-based LAM tests in children, the following scientific aims were the 
in main focus: 
- Description of diagnostic accuracy of urine-based LAM assays compared to culture as a 
reference standard in children with suspected pulmonary TB and with and without HIV co-
infection (64). 
- Description of factors that are associated with TB detection by urine LAM to define the 
preferred target (sub-) group for LAM-based TB diagnosis in children (64). 
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2.3. TB prevalence and risk factors in Ethiopian prisons 
A second focus of this habilitation project was the investigation of TB prevalence and various risk 
factors related to TB among prisoners in Ethiopian prisons. The following questions were addressed: 
- What is the TB prevalence in Ethiopian prisons, and  
- What are the key risk factors for the diagnosis of active TB in Ethiopian prisons (65)? 
2.4. Genotypic characterization of isolated TB strains from research studies from Ethiopia and 
Tanzania 
Finally, the isolated TB strains from the different Tanzania and Ethiopian studies were further 
characterized using genotyping methods. The following objectives were addressed in two sub-studies: 
- What are the characteristics of TB strains isolated from Ethiopian prison inmates compared to 
those from the normal population? Which conclusions can be drawn concerning the TB 
transmission routes in the Ethiopian population and prisons (66)?  
- Is there an association between specific MTB genotypes and the degree of immune-
suppression in ART-naïve individuals diagnosed with active pulmonary TB and HIV coinfection 
in Tanzania (67)? 
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3. Scientific projects 
3.1. Research studies performed at NIMR-Mbeya Medical Research Center (NIMR-MMRC)  
The data for the evaluation of the TB diagnostic tests, namely the Xpert MTB / RIF assay and the urine-
based LAM tests, were originating from several clinical research studies conducted at the NIMR-MMRC 
(National Institute of Medical Research, Mbeya Medical Research Center) in collaboration with the 
Department for Infectious Diseases and Tropical Medicine of the LMU. Most of these studies have 
been carried out and/or supervised by me as Head of the Department of Clinical Tuberculosis Studies 
at NIMR-MMRC, from 2009 to 2012. In addition to the coordination and supervision of data collection 
in the clinic and in the tuberculosis laboratory, I contributed to the development of the various student 
designs. The processing of the data as well as the data analysis I performed either independently or in 
close cooperation with coauthors, and as supervisor of the master thesis of Dr. Nyanda Elias Ntinginya. 
3.1.1. “Evaluation of transrenal-DNA detection to diagnose tuberculosis (TB Tr-DNA)” 
The TB Tr-DNA diagnostic study was performed at the NIMR-MMRC in Tanzania to develop a new PCR-
based test that is suitable for detecting pulmonary tuberculosis in the urine of symptomatic patients. 
The main clinical study was developed by scientists from LMU, the NIMR-MMRC and the University 
College, London, and completed by early 2009. In short, approximately 300 patients with TB suspicion 
were recruited from July 2007 to September 2007 in order to determine the diagnostic performance 
of the urine-based PCR tests. In addition to urine samples, sputum was also collected and used as a 
reference standard for the diagnosis of pulmonary tuberculosis by means of microscopy and culture. 
The collected sputum samples were frozen at -80°C for future studies. The isolated TB strains were 
sent to the German reference laboratory in Borstel for further analysis.  
For the evaluation of the Xpert MTB/RIF test, the frozen sputum samples of the TB Tr-DNA study were 
systematically used to investigate the diagnostic capacity of the new Xpert test, between January 2010 
and March 2010. The planning of the study, the performance of the test in the laboratory, as well as 
the data entry and data processing on the NIMR-MMRC took place under my supervision. I carried out 
the data analysis together with the statistician of our working group (Dr. Elmar Saathoff) and my then 
working group leader (Prof. Michael Hoelscher) at LMU. The study results were subsequently published 
in PLosOne in 2011 (60). 
In a further sub-study, the isolated TB strains were used to investigate the correlation between the 
detection of different genotypes and the degree of immunosuppression in HIV-positive TB patients. 
The TB Tr-DNA cohort (as well as the REMox TB cohort, see below) was particularly well suited for this 
analysis because of the high proportion of HIV-positive subjects with TB. I was involved in the 
development of the study design. I carried out the data analysis together with a colleague (Dr. Ioana 
Olaru) and a statistician from Research Center Borstel. The data were published in the International 
Journal of TB and Lung Diseases in 2014 (67). 
3.1.2. “Active Detection of Active TB (ADAT) in Children” 
Within the frame of the multi-site ADAT project, a prospective cohort study was carried out at NIMR-
MMRC, between May 2008 and November 2010, in approximately 200 children with clinical suspicion 
of TB. The aim was to evaluate various new diagnostic TB tests in children against culture or a clinical 
reference standard for TB diagnosis, among those the Xpert MTB/RIF assay and two different urine-
based LAM assays as part of this habilitation project. In order to observe the clinical course with or 
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without TB therapy (as a possibility of indirect TB diagnosis in children with negative TB culture) or to 
be able to make alternative clinical diagnoses in the further course (thus exclusion from TB), the 
children were examined up to one year after inclusion in the study. As of May 2009, I was involved in 
the supervision of data collection (clinical data and laboratory data). I was also involved in the clinical 
care of the children. As the basis for the data analysis and evaluation of all diagnostic tests, I defined 
the final (TB) diagnosis and/or alternative diagnoses of the study participants with my medical 
colleague at NIMR MMRC (Dr. Petra Clowes), taking into account clinical, radiological and 
microbiological data. I continued to supervise data management and was involved in the statistical 
analysis of the study data. The results of this research were published in Clinical Infectious Diseases in 
2012 (61) and in the European Respiratory Journal in 2015 (64). 
3.1.3. “TB screening in household contacts of pulmonary TB patients using Xpert MTB/RIF assay” 
As the local supervisor of the MSc thesis of Dr. Nyanda Elias Ntinginya (MD), I was decisively involved 
in the conceptual design, as well as in the data collection and analysis of this Xpert MTB/RIF evaluation 
study. Two hundred and nineteen household members of 80 sputum smear-positive TB patients were 
recruited and examined for the presence of TB bacteria in their sputum, using smear microscopy, MTB 
culture and Xpert MTB/RIF test between April 2011 and June 2011. The results were published in the 
International Journal of Tuberculosis and Lung Diseases in 2012 (62). 
3.1.4. “Controlled comparison of two moxifloxacin containing treatment shortening regimens with 
the standard regimen in pulmonary tuberculosis: REMox TB” 
This study was a placebo-controlled, double-blinded therapeutic study in which moxifloxacin was 
evaluated as a component of shortened antibiotic TB combination therapy compared to standard 
therapy (2 months rifampicin, isoniazid, ethambutol and pyrazinamide plus 4 months rifampicin and 
isoniazid) (68). It was a multicenter study funded by the EDCTP and the TB Alliance, which was carried 
out among other sites at the NIMR-MMRC from March 2009 until March 2014. In my role as head of 
the Department of Clinical Tuberculosis Studies, I was responsible for the coordination and supervision 
of the study in the field of clinical, laboratory and data collection as well as for the medical care of the 
study patients on site. 
As a sub-study, together with my working group leader at LMU (Prof. Michael Hoelscher) and our 
colleagues in Cape Town (Prof. Andreas Diacon, Dr. Sven Friedrich), we developed the idea of an 
evaluation study for the Xpert MTB/RIF as a therapeutic marker for pulmonary TB patients. For this 
purpose, the frozen sputum samples of approximately 260 REMox TB patients from Mbeya (Tanzania) 
and Cape Town (South Africa) were tested systematically by the Xpert MTB/RIF assay for various study 
time points up to 1.5 years after TB diagnosis in order to analyze the capacity of Xpert MTB/RIF assay 
to monitor TB treatment response compared to standard diagnostics. In addition to the concept of the 
study, I was involved in data processing and analysis (together with Dr. Elmar Saathoff). The study was 
published in Lancet Respiratory Medicine in 2013 (63).  
3.2. Prison studies in Ethiopia 
From December 2012 to May 2015, the Department for Infectious Diseases and Tropical Medicine of 
the LMU, conducted an EDCTP-sponsored multicenter study at various African study centers. The 
project was called "Epidemiology of PZA resistance in TB Clinical trials in Africa - an essential 
prerequisite for evaluating novel TB drug combinations" and had the main goal of investigating the 
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occurrence of drug resistance, with major focus on pyrazinamide resistance, in different study 
populations in Africa. I supervised this multi-center study as co-investigator and scientific co-ordinator 
at the Department for Infectious Diseases and Tropical Medicine of the LMU. Within the scope of this 
project, new TB studies or TB study sites were setup in order to expand the study population to as 
many African countries as possible. One of these newly initiated research projects was a tuberculosis 
jail study, which was conducted in 13 Ethiopian zonal prisons and covering more than 15.000 
incarcerated persons from January 2013 until December 2013. Mr. Ali Mohammed, who initiated and 
supervised the study at the ground in Jimma, Ethiopia, was enrolled as a PhD student at the Center for 
International Health (CIH) at the LMU since October 2012 and I supervised his PhD work as a direct 
supervisor. In this function, I was involved in the conception of the prison study as well as in the 
development of the methodology. Later, I supervised the statistical evaluation and the publication of 
the data in 2015 and 2016 (65, 66).  
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4. Results and interpretation 
4.1. Evaluation of the diagnostic performance of Xpert MTB/RIF assay in Tanzanian adults with 
clinical suspicion of TB and high HIV-coinfection rate 
A retrospective, cross-sectional diagnostic evaluation study was performed, using bio-banked sputum 
samples, which were stored from all participants of the Tr-DNA study (see paragraph 3.1.1 above). In 
this study, 292 adults were consecutively enrolled, who presented themselves with clinical suspicion 
of active TB to the TB study clinic at NIMR-MMRC or to another collaborating health center. From all 
292 subjects, three sputum samples (two spot sputum samples and one morning sputum sample) were 
collected for the diagnosis of TB, using smear microscopy and culture methods on liquid and solid 
media, and consecutive storage. Later, the same, thawed sputum samples were used for Xpert 
MTB/RIF evaluation. For the calculation of the diagnostic performance of Xpert MTB/RIF test, culture 
confirmed TB was used as reference standard. 
Among the 69 (23.6% of 292) participants with microbiologically confirmed TB, the sensitivity of Xpert 
MTB/RIF reached 88.4% (95%CI: 78.4%-94.9%). In those 103 (35.3% of 292) participants in whom active 
pulmonary TB disease could be definitely excluded, the specificity was 99.0% (95%CI: 94.7%-100%). Of 
note, there was a significant difference in the sensitivity of the Xpert MTB/RIF test in sputum smear 
positives versus sputum smear negatives, with 98.0% (95%CI: 89.6%-100.0%) versus 61.1% (95%CI: 
35.7%-82.7%), respectively (p< 0.001). There was no difference in the performance of the Xpert 
MTB/RIF assay among HIV-positive and HIV-negative study participants (HIV-prevalence in study: 
58.9%, 95%CI: 45.0%-89.9%). The Xpert MTB/RIF correctly identified seven (9.1%) additional TB 
patients in the group of 77 (26.4% of 292) participants who had a clinical TB diagnosis (all of them were 
treated for TB and showed clinical improvement within eight weeks follow up) but were negative for 
TB in sputum culture. All of these seven patients were HIV-coinfected and were Xpert MTB/RIF positive 
in multiple sputum samples. None of them had a history of TB in the past. Interestingly, there was no 
significant difference in Xpert MTB/RIF sensitivity when only one morning sputum or three sputa (1 
morning sputum plus 2 spot sputa) were tested. Finally, we could show a good correlation of 
quantitative Xpert MTB/RIF readouts (CT-value) with smear microscopy grade and time to positivity 
(TTP) in liquid culture (MGIT).  
This study provided first information on specific diagnostic performance characteristics of Xpert 
MTB/RIF assay, which were also relevant for the designs and objectives of following evaluation studies 
and were later confirmed by other studies from developing countries. First, Xpert MTB/RIF assay could 
be run under field conditions without any technical problems. Second, Xpert performed equally well 
in HIV-positive and HIV-negative TB suspects. Third, only one sample needed to be tested to reach 
maximal sensitivity of the assay in adults. And finally, Xpert MTB/RIF detected additional TB cases who 
were M.tb culture negative. However, this study also indicated that the sensitivity of the Xpert 
MTB/RIF test is significantly reduced in the group of smear negative TB patients. 
 
4.2. Evaluation of the diagnostic performance of Xpert MTB/RIF assay in a Tanzanian children cohort 
with clinical suspicion of TB and high proportion of HIV-coinfection  
To evaluate the diagnostic accuracy of Xpert MTB/RIF in children and estimate the impact of the test 
on time to diagnosis and anti TB treatment initiation we used the sputum samples from 164 children 
with presumed TB who were enrolled in a prospective cohort and were followed for a minimum time 
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of 12 months. Sixty nine (42.07% of 164) children were hospitalized at recruitment, the remaining 
children were recruited from the ambulant sector. Up to three sputum samples (induced and not 
induced sputum samples) from each participant were collected at recruitment for TB diagnosis using 
smear microscopy, solid and liquid culture and Xpert MTB/RIF test.  
All children, in whom active TB disease could be reliably excluded, were also detected as negative by 
Xpert MTB/RIF, resulting in a specificity of 100%. Xpert´s sensitivity was 75% (95%CI: 55.1%-89.3%) 
with 21 detected children out of 28 children with culture confirmed TB. Among the seven smear 
positive children sensitivity was even 100% (95%CI: 59.0%-100.0%), while Xpert MTB/RIF detected only 
66.6% (95%CI: 43.0%-85.4%) of smear negative children (14 out of 21). In the per sample analysis of 
77 sputum samples which were collected from the 28 children with culture confirmed TB, the 
sensitivity of smear microscopy, solid culture, liquid culture and Xpert MTB/RIF was 19.5%, 55.3%, 
54.2% and 54.2%, respectively. Notably, Xpert MTB/RIF test detected four additional TB cases 
(sensitivity of 8.5%) among 47 children with highly probable clinical TB diagnosis. Testing a second and 
third sputum sample increased the overall sensitivity of Xpert MTB/RIF by 20% and 16%, respectively. 
Importantly, the chance of a Xpert positive sputum result was increased in children of older age and 
more advanced disease, while the HIV-status (cohort prevalence: 51.2%) played no significant role. 
Median time from enrolment to TB diagnosis for smear, Xpert (retrospectively calculated), liquid 
culture and solid culture was 1 day (range 1-3), 2 days (range 1-12), 21 days (range 11-59) and 30 days 
(range 14-79), respectively. Initiation of anti TB treatment was delayed by up to 59 days in 9 out of 28 
children with culture confirmed TB and two children with confirmed TB were lost while the culture 
result was pending. As Xpert MTB/RIF results did not inform treatment decision it could only be 
speculated that Xpert-based TB diagnosis could not only shorten time to diagnosis but also reduce time 
to treatment start and number of children untreated for TB.  
The diagnostic performance of Xpert MTB/RIF in children with culture confirmed TB was comparable 
to that found in adults, namely with a significant difference in sensitivity among smear-positive and 
smear-negative TB cases. Like in adults, HIV-status played no role for Xpert MTB/RIF performance in 
children. Most important in this study was to show that Xpert tripled the number of children (25 
children with positive Xpert MTB/RIF results) with a potentially rapid TB result compared to when only 
smear microscopy (7 smear positive children) would be available. Opposed to results from adult 
studies, we showed, however, that up to three sputum samples need to be tested to reach the maximal 
sensitivity of the test.  
4.3. Evaluation of the diagnostic performance of Xpert MTB/RIF in an active case finding strategy 
The aim of this cross-sectional study was to access the feasibility and accuracy of Xpert MTB/RIF assay 
in the context of TB contact tracing among household contacts of smear-positive TB cases.  
Two hundred and nineteen (219) household contacts, who were living in the same house or plot and 
shared meals together with 80 smear-positive index cases, were enrolled in this study. Out of these, 
33 contacts could provide up to two spot sputum samples (56 sputum samples in total). All samples 
were tested for TB with culture methods (MGIT and LJ), smear microscopy and Xpert MTB/RIF assay. 
In total, five household contacts were M.tb culture positive, resulting in a TB prevalence of 2.3% 
(95%CI: 0.7-5.2%), which is equivalent to 2.300 TB cases per 100.000 house hold contacts and a number 
of 43.8 (95%CI: 19.1-134.2) needed to be screened to detect one TB case. Among those, who could 
provide at least one sputum sample, the proportion of TB-positives was 15.2% (5/33, 95%CI: 5.1%-
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31.9%), the number to be screened to detect one case was 6.6 (95%CI: 3.1-19.6) and the point 
prevalence was 15.200 TB cases among 100.000 households contacts with sputum production. Xpert 
MTB/RIF detected all culture-confirmed cases, 5 out of 5, resulting in a sensitivity of 100% (one-sided 
97.5%CI: 47.8%-100%). The sensitivity of smear microscopy was 60% (3/5, 95%CI: 14.7%-94.7%). In all 
TB cases already the first sputum sample collected was tested positive by Xpert MTB/RIF assay. No 
additional cases nor rifampicin-resistance were detected by Xpert. 
Despite the small study size, the data indicated that Xpert MTB/RIF testing is a feasible, fast and 
accurate method for TB tracing among household contacts. Further, the high sensitivity compared to 
sputum culture and the challenge of low volume (~ 1ml) of many sputum samples support the use of 
the Xpert MTB/RIF as a single diagnostic test. Especially in this cohort, with a high proportion of 
asymptomatic and paucibacillary TB cases the Xpert MTB/RIF was shown to be superior to smear 
microscopy. The cost effectiveness and the impact of TB contact tracing using Xpert MTB/RIF has to be 
proven in greater studies and also for further settings. 
4.4. Assessment of the Xpert MTB/RIF assay as a sputum biomarker of response to TB treatment 
In the absence of a useful biological biomarker for the monitoring of response to anti TB treatment, 
we evaluated the diagnostic accuracy of Xpert MTB/RIF assay against sputum culture and smear 
microscopy in a clinical cohort of smear-positive TB patients who were enrolled in the REMox TB trial, 
a randomized placebo controlled phase III therapeutic drug trial (ClinicalTrials.gov, NCT00864383).  
In this substudy, 2741 sputum samples were analysed which were collected from 221 patients over a 
treatment period of 26 weeks. While only 29% (62 out of 212), 26% (46 out of 176) and 42% (77 out of 
183) of samples were positive for smear, LJ and MGIT, respectively, at week eight after TB treatment 
initiation, 84% (174 out of 207) of samples were still positive for Xpert. Further, 5% (10 out of 199), 3% 
(4 out of 157) and 4% (7 out of 169) of samples were positive for smear microscopy, LJ and MGIT, 
respectively, at the end of TB treatment, while 27% (22 out of 83) were still positive with Xpert MTB/RIF 
assay. Compared to smear microscopy and culture methods as combined reference standard, Xpert 
MTB/RIF had a high overall sensitivity of 97.0% (95%CI: 95.8%-97.9%) but poor specificity of 48.6% 
(95%CI: 45.0%-52.2%). The quantitative readouts of Xpert MTB/RIF (CT-value), smear microscopy 
(positivity grade), LJ (positivity grade) and MGIT (TTP) correlated very well until week 8 of treatment, 
with poorer correlation thereafter, resulting in an overall correlation coefficient of -0.74, -0.73 and 
0.73 for smear microscopy, LJ and MGIT, respectively. 
During the time point of data analysis for this substudy, the main REMox TB Trial was still ongoing. To 
avoid interference with the endpoints and main analysis of the main treatment trial, the sample 
analysis with Xpert MTB/RIF assay was restricted until week 26 and did not include TB treatment 
outcome data at week 26. Further, all investigators were masked to the treatment allocations of the 
patients included when this substudy was published. The poor specificity of Xpert MTB/RIF assay 
precludes the use of the test as biomarker for treatment response in its current format. It is open to 
show whether modifications of the sample processing and testing protocol could avoid the detection 
of DNA related with destroyed or non-viable mycobacteria. Further data analysis and additional studies 
are awaited to assess whether a positive Xpert MTB/RIF result at the end of TB treatment or a high 
bacterial burden measured at treatment beginning can predict treatment failure or relapse. 
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4.5. Analysis of performance of urine-based LAM-assays in a Tanzanian paediatric cohort with 
presumed TB and high proportion of HIV-coinfection 
To evaluate the diagnostic accuracy of two different urine based LAM-assays (MTB-LAM ELISA assay 
from Chemogen and the Determine TB-LAM strip test from Alere) in children with TB symptoms, and 
to assess patient characteristics which might be associated with a positive LAM-result, we used urine 
samples from the same paediatric cohort, with an HIV-prevalence of 51%, which was enrolled to 
evaluate the performance of Xpert MTB/RIF assay in sputum samples (see paragraph 3.1.2 and 4.2 
above).  
Out of 132 children who were included in the final analysis, 18 (13.64% out of 132) were diagnosed 
with culture confirmed TB and 36 (27.27% out of 132) children were classified as highly probable TB 
cases. In those with culture confirmed TB, the sensitivity of the ELISA assay was 44% (95%CI: 22%-69%) 
and that of the strip test was 28% (95%CI: 10%-54%). In the subgroup analysis of HIV-positive 
confirmed TB cases, the sensitivity was 70% (95%CI: 35%-93%) and 50% (95%CI: 19%-81%) for the ELISA 
and strip test, respectively, while it was 13% (95%CI: 0%-53%) for the ELISA test and 0% (95%CI: 0%-
37%) for the strip test in the subgroup of HIV-negative culture confirmed TB cases. Both test found 
additional TB cases, 6 (17%) out of 36 detected by ELISA assay and 2 (6%) detected by the strip test, in 
the group of children with highly probable TB. Both tests provided negative result for all children in 
whom active TB could reliably excluded, resulting in a specificity of 100% (95%CI: 84%-100%). A 
positive LAM ELISA result was highly and independently associated with HIV (p=0.04), proteinuria 
(p=0.019), low BMI (p=0.02) and one year mortality (p=0.032). In all but one (positive until month 7) 
children with a positive LAM result at the beginning of anti-TB therapy the test turned negative after 
three months of TB treatment. 
Opposed to sputum samples in children, urine samples are a relatively easy to collect specimen and 
are therefore an attractive target for new diagnostic assays specifically designed for diagnosis of 
childhood TB. This study indicated that specifically HIV-positive children with presumed active TB 
infection might benefit from urine LAM-testing, especially in resource limited settings where culture 
methods and even Xpert MTB/RIF assay might not be available. This assumption is further supported 
by the fact that those cases with advanced disease (proteinuria, low BMI, high mortality) seem to be 
more likely to be detected by LAM-tests and thus, could benefit from an early TB diagnosis and 
treatment initiation. The observation of LAM-conversion during TB treatment among those with a 
positive test at baseline was shown for the first time in children and calls for further studies to explore 
the capacity of LAM-assays to monitor TB treatment in children. 
4.6. TB prevalence and associated risk factors in Ethiopian zonal prisons 
A cross-sectional research study was conducted in 13 zonal prisons in South Ethiopia, Southwest and 
Southeast Ethiopia, from January 2013 until December 2013. The WHO TB symptom screening 
algorithm was applied (69) to identify prisoners with high probability levels of TB. Those with a positive 
screening result, were asked to provide two sputum samples for smear and microscopy and MTB 
culture on solid media (LJ). A standardized questionnaire was used to collect information on risk factors 
from all prisoners with collected sputum samples.  
In total, 15.495 inmates were included in the TB symptom screening, out of whom 765 prisoners (4.9%, 
95%CI: 4.6%-5.2%) had TB symptoms and were screened for TB by microscopy and culture. Among the 
765 TB suspects, 51 (6.67%) were already on TB treatment and 20 (2.8%) new TB cases could be found. 
This results in a TB prevalence of 9.2% (71/765; 95%CI: 7.2%–11.4%) among TB suspects and of 0.46% 
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(71/15.495; 95%CI: 0.35–0.57) among all prisoners. There was a great range in TB prevalence among 
the different prisons and Ethiopian states: the highest TB prevalence was observed in Dilla prison 
(SNNPRS) with 1.528 cases per 100.000 inmates (1.53%). Among the different regional states the 
SNNPRS had the highest tuberculosis burden with an overall prevalence of 618.8 (95%CI: 420–820) per 
100.000 inmates (0.62%). We found a linear trend in prevalence of tuberculosis with advancing 
distance of the prisons from the centre of Ethiopia (Addis Ababa). Prisons within a radius of below 
200km distance from Addis Ababa had the lowest TB prevalence of 97.98 (95%CI: 10–210) per 100.000 
inmates while the highest TB prevalence of 804 (95%CI: 580–1020) per 100.000 inmates was observed 
in prisons located more than 400km away from Addis Ababa, (OR = 3.60, 95%CI: 2.24–5.70, p<0.0001). 
Apart from that, additional risk factors which were significantly associated with TB were presence of 
window in prison cell (AOR: 0.26, 95%CI: 0.16–0.45, p-value: <0.001), alcohol consumption in the past 
(AOR: 2.04, 95%CI: 1.20–3.46, p-value: 0.008) and contact with a TB case before imprisonment (AOR: 
1.49, 95%CI: 1.08–2.06, p-value: 0.02).  
Our research results indicated, that the average TB prevalence in Ethiopian prison inmates is twice 
higher than the prevalence in the general population, although a great variability of prevalence among 
different prisons existed. This variability, the fact that only 28% of TB cases were newly diagnosed (20 
out of 71), and the TB risk factors found in this study suggest that the presence of TB in Ethiopian 
prisons is associated to both, factors inherent to the prisons (implementation of TB prevention 
methods, TB diagnosis and treatment) and also inherent to TB patients (contact to TB case, alcohol 
consumption). The results of this study support the notion that TB epidemics in communities and 
prisons are closely interrelated. Risk factors of both groups, prisoners and communities, needs to be 
addressed in order to control TB sufficiently at the population level. 
4.7. Further characterization of MTB strains isolated from Ethiopian and Tanzanian populations 
The MTB strains, which were isolated within the different research studies in Ethiopia and Tanzania 
were further analyzed in the frame of various research collaborations of the Department for Infectious 
Diseases and Tropical Medicine of the LMU, Germany, with the Research Center in Borstel, Germany. 
In the first study, Ethiopian MTB strains from prisoners and hospitalized community members were 
analysed and compared. In total, for 109 MTB strains (21 strains from prisoners and 88 strains from 
hospitalized TB patients) the phenotypic drug resistance pattern and genotyping results (24 loci MIRU-
VNTR and spoligotyping) were available. The majority (27.52%) of the strains belonged to 
Ethiopia_H37RV like, followed by Ethiopia_3 (16.51%) and Delhi/CAS (16.51%) lineages and there was 
no statistical difference between prisons and communities with regards to the diversity and pattern of 
MTB genotypes. However, the genotype patterns from different Ethiopian regions were differing 
significantly. In the cluster analysis, 12 clusters of two to eight strains of size were identified with a 
total clustering rate of 31.19%. Interestingly, clustering rates were not different between prisons and 
communities but, again, between different regions and different linages. Of note, two clusters included 
MTB strains from prisoners and community members. Clustering was not associated with drug 
resistance. Further, MDR prevalence in community isolates was 2.27% (2 out of 88) whereas it was 
9.52% in prison isolates (2 out of 21, with one isolate from an inmate with previous history of TB), 
however, this difference was not statistically significant, (p = 0.112). In conclusion, this study suggested 
that the appearance of TB in prisons and communities are closely interrelated: MTB strains from both 
settings share the same genotypic pattern and clustering rates and even build the same clusters, thus, 
prisons as an integral part of civil societies need to be included in NTP strategies aiming for TB control. 
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In the second study, we investigated the association of TB infection with specific MTB linages, 
characterized by spoligotyping and MIRU-VNTR, and the degree of immune- suppression measured by 
circulating CD4 lymphocytes. The hypothesis was, that ART-naïve HIV-infected individuals with mild 
immune suppression develop active TB disease, which is caused by more virulent MTB strains 
compared to those HIV-infected TB patients with severe immune suppression. One hundred and 
twenty nine MTB strains, which were collected in different research studies, performed at the NIMR-
MMRC, were included in this project. Sixty (46.5%) participants had advanced immune-suppression 
(CD4 count </= 200/mm3). The majority of TB strains (n=55; 42.6%) belonged the Latin American 
Mediterranean (LAM) lineage, followed by Delhi/Central-Asian (CAS) (n=37; 28.7%) lineages. There was 
no significant association between the type of lineages identified (in total 8 different lineages) and the 
level of immune-suppression in HIV-positive TB patients. The most likely explanation for this finding 
was that all identified lineages have comparable in vivo virulence in HIV-infected individuals. 
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5. Conclusions 
New diagnostics are needed to control TB globally and, specifically, in Africa. Especially, for particular 
sub-Saharan African risk populations, such as children, HIV-positives or prisoners, where the current 
standard diagnostics are either lacking diagnostic accuracy or are not feasible and affordable, 
innovative testing strategies are required to increase the number of microbiologically confirmed and 
correctly treated TB cases.  
The endorsement of the automated molecular Xpert MTB/RIF assay by WHO in December 2010 hold 
promise to fundamentally change TB diagnosis (and diagnosis of MDR-TB) in African and other 
resource-limited settings. This habilitation project contributed to the clinical evaluation of Xpert 
MTB/RIF in African populations, mainly by the assessment of the assay´s diagnostic accuracy in various 
study populations and context. The main test characteristics summarized by the research results of 
this habilitation project were confirmed by different authors and are also reflected by the current 
global testing strategy for Xpert MTB/RIF recommended by WHO (70). Precisely, Xpert MTB/RIF should 
preferably applied in adults and children with HIV-associated TB. Further, the WHO recommendations 
support the use of a single sputum sample for TB diagnosis with Xpert MTB/RIF (70). As the Xpert 
MTB/RIF evaluation studies demonstrated in this project were mostly performed retrospectively the 
derived conclusion were limited to diagnostic accuracy parameters. Therefore, the calculated 
estimates related to impact on patient level (time to diagnose and treatment initiation, TB-related 
morbidity and mortality) need to be interpreted with caution and may vary between different settings. 
Further, while generalizability of diagnostic performance results was confirmed by several studies from 
other African and resource limited settings, the final judgement on Xpert MTB/RIF assay as marker for 
TB treatment response and, even more important, for treatment outcome is still outstanding. 
Additionally, although cost-effectiveness compared to previous diagnostic algorithms could be shown 
for Xpert MTB/RIF assay in different studies (70), the assay´s impact on patient-relevant outcome 
parameters (morbidity and mortality) was not yet sufficiently investigated (38). Further, the 
epidemiological impact (e.g. TB incidence and prevalence) of the implementation of this assay is still 
to be proved. 
Opposed to Xpert MTB/RIF assay, the role of urine-based LAM-assays in the diagnosis of TB is still not 
defined. This is mainly due to the limited scientific evidence on the diagnostic accuracy and impact of 
the application of LAM-assays in different populations (71). E.g. apart from the publication resulting 
from this habilitation project there was only a maximum of four further studies published on the 
evaluation of LAM assays in children in 2015 (71). Further, the majority of available studies were either 
not comparable or of poor quality (71). Current WHO guidelines (for adults and children) do not 
suggest to use the LAM test as a single test for TB diagnosis. However, the assay should be considered 
to support TB diagnosis in HIV-positive TB subjects who are severely ill. The data of this habilitation 
project support this strategy, showing the highest sensitivity in HIV-positive TB cases and those with 
advanced morbidity and high mortality. Although, a reduction in time to treatment initiation and, by 
that, also, in mortality, could be shown for LAM strip test in one prospective study with adult, 
hospitalized and HIV-positive TB suspects (72), further research is needed to better define the testing 
strategy, clinical setting(s) and the target populations for this test. 
The presented data from Ethiopia confirmed that TB in African prisons is a relevant health problem 
and poses a relevant threat to TB control in communities. Even with using a relative insensitive TB 
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screening method (strict symptom screening (69), followed by smear microscopy plus sputum culture 
on LJ in symptomatic subjects) TB prevalence in Ethiopian prisons was twice higher than in the normal 
population. In addition to well known risk factors for TB in prisons (e.g. alcohol consumption, 
circulation of air) our data provide further evidence for the interrelation of the two TB epidemics, 
inside and outside prison facilities. Precisely, active TB cases in prisons were more likely to have had 
contact with a TB case before imprisonment compared to healthy prison inmates, and the genotypic 
analysis revealed that TB strains from inside prison facilities build clusters together with TB strains from 
the normal population indicating that they were sharing the same source of TB infection. Prisoners are 
usually originating from vulnerable groups of society, e.g. drug and alcohol dependent, poor, homeless 
or mentally ill people, etc., who have per se a high risk for TB. In detention facilities, they meet an 
environment which amplifies that risk by malnutrition, overcrowding and extremely poor housing 
conditions. Therefore, active TB screening among prisoners, including both those who newly enter 
detention facilities and those who stay in prisons for a longer time period, should be scaled up and 
empowered by better staff and improved diagnostics, as it has a high potential to detect many new TB 
cases among those community members who carry the greatest TB risk but are considered difficult to 
reach by common screening programmes and by that improve TB control in sub-Saharan Africa. 
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Abbreviations and acronyms 
 
ADAT Active Detection of Active TB 
AOR Adjusted Odds Ratio 
CI Confidence Interval 
CIH Center for Internal Health 
CT-value Cycle Threshold-value (in PCR) 
DNA Deoxyribonucleic Acid 
DOTS Direct Observed Treatment, Short Course 
EDCTP European & Developing Countries Clinical Trials Partnership 
e.g. exempli gratia 
FIND Foundation for Innovative New Diagnostics 
HIV Human Immunodeficiency Virus 
IGRA Interferon Gamma Release Assay 
LMU Ludwig-Maximilians-Universität 
LAM Lipoarabinomannan 
MD Medical Doctor 
MDG Millenium Development Goals 
MGIT Mycobacteria Growth Indicator Tube 
Mio Million 
MIRU-VNTR Mycobacterial Interspersed Repetitive Unit-Variable Number Tandem Repeats 
MMRC Mbeya Medical Research Center 
MTB Mycobacterium Tuberculosis 
NIMR National Institute of Medical Research 
NTM Nontuberculous Mycobacteria 
NTP National TB Program 
OR Odds Ratio (not adjusted) 
PCR Polymerase Chain Reaction 
RIF Rifampicin 
SDG Sustainable Development Goals 
TB Tuberculosis 
TR DNA Transrenal Deoxyribonucleic Acid 
TTP Time To Positivity 
US United States (of America) 
WHO World Health Organisation 
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